Research programme: biosimilar human protein therapeutics - Inbiopro Solutions

Drug Profile

Research programme: biosimilar human protein therapeutics - Inbiopro Solutions

Alternative Names: Biosimilars- Inbiopro Solutions; IBPB 004IG; IBPB 005ET; IBPB 006IA; IBPB 007IL; IBPB 008IG

Latest Information Update: 16 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inbiopro Solutions
  • Class Interleukins; Proteins
  • Mechanism of Action Bone marrow cell stimulants; Cytotoxic T lymphocyte stimulants; Interleukin 1 receptor antagonists; Leukocyte stimulants; Natural killer cell stimulants; Neutrophil stimulants; Plasmin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Acute myeloid leukaemia; Chronic granulomatous disease; Chronic hepatitis; Hairy cell leukaemia; Myocardial infarction; Neutropenia; Osteoporosis; Rheumatoid arthritis; Stroke

Most Recent Events

  • 31 Dec 2009 Suspended - Preclinical for Acute myeloid leukaemia (adjunctive therapy) and Neutropenia (adjunctive therapy)in India (unspecified route)
  • 31 Dec 2009 Suspended - Preclinical for Myocardial infarction and Stroke in India (unspecified route)
  • 30 Jun 2009 Suspended - Preclinical for Chronic hepatitis (B or C) and Hairy cell leukaemia in India (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top